Guangdong Zhongsheng Pharmaceutical Dirección

Dirección controles de criterios 3/4

El CEO de Guangdong Zhongsheng Pharmaceutical es Yong Hong Chen, nombrado en Jan 2011, tiene una permanencia de 13.83 años. posee directamente un 1.62% de las acciones de la empresa, con un valor de CN¥178.68M. La antigüedad media del equipo directivo y de la junta directiva es de 5.9 años y 4.9 años, respectivamente.

Información clave

Yong Hong Chen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	13.8yrs
Participación del CEO	1.6%
Permanencia media de la dirección	5.9yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Yong Hong Chen (53 yo)

13.8yrs

Permanencia

CN¥498,700

Compensación

Mr. Yong Hong Chen serves as General Manager of Guangdong Huanan Pharmaceutical Group Co., Ltd. and Guangdong Zhongsheng Pharmaceutical Trade Co., Ltd. Mr. Chen serves as Executive Director of Guangdong Zh...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yong Hong Chen	Chairman & President	13.8yrs	CN¥498.70k	1.62% CN¥ 178.7m
Yuchong Zhang	Vice Chairman & Senior VP	7.9yrs	CN¥311.50k	10.95% CN¥ 1.2b
Chun Hua Long	VP, CFO	14.8yrs	CN¥372.90k	0.43% CN¥ 47.0m
Xi Ping Zhao	VP & Director	1.9yrs	CN¥372.90k	0.92% CN¥ 101.3m
Shuang Liu	Vice President	5.9yrs	CN¥547.40k	sin datos
Wei Yang	Board Secretary	1.5yrs	sin datos	sin datos
Rikang Luo	Vice President	less than a year	sin datos	0.0012% CN¥ 130.2k

5.9yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 002317 es experimentado (5.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yong Hong Chen	Chairman & President	13.8yrs	CN¥498.70k	1.62% CN¥ 178.7m
Yuchong Zhang	Vice Chairman & Senior VP	7.9yrs	CN¥311.50k	10.95% CN¥ 1.2b
Chun Hua Long	VP, CFO	10.8yrs	CN¥372.90k	0.43% CN¥ 47.0m
Xi Ping Zhao	VP & Director	1.9yrs	CN¥372.90k	0.92% CN¥ 101.3m
Wen Tan	Non-Independent Director	4.9yrs	CN¥72.00k	sin datos
Pengan Shan	Non-Independent Director	7.9yrs	CN¥72.00k	sin datos
Ruichao Lin	Independent Director	4.9yrs	CN¥72.00k	sin datos
Qinggong Wu	Independent Director	4.9yrs	CN¥72.00k	sin datos
So Hyun Lee	Supervisor	7.9yrs	sin datos	sin datos
Xiaorong Mou	Independent Director	2.5yrs	CN¥45.00k	sin datos
Zhenyou Tan	Chairman of the Supervisory Board	1.9yrs	sin datos	sin datos
Hougan Huang	Employee Supervisor	less than a year	sin datos	sin datos

4.9yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: La junta directiva de 002317 se considera experimentada (4.9 años de antigüedad promedio).

Guangdong Zhongsheng Pharmaceutical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Board Elections

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.084 (vs CN¥0.082 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.088 in 2Q 2023)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dividend of CN¥0.20 announced

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.17 in 1Q 2023)

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 26%

Investor sentiment deteriorates as stock falls 17%

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: CN¥0.082 (vs CN¥0.059 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Second quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.16 in 2Q 2022)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 May 2023

Investor sentiment deteriorates as stock falls 20%

Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.35 in FY 2021)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Board Elections

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.032 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.29 in 2Q 2021)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 678.8 million in funding

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Cash Dividend, Payable on May 27, 2022

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2021

Investor sentiment deteriorated over the past week

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.07 in 1Q 2021)

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.032 (vs CN¥0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.17 in 2Q 2020)

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2020

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2020

First quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.07 in 1Q 2020)

New 90-day low: CN¥8.13

New 90-day low: CN¥9.73

New 90-day low: CN¥12.06

New 90-day low: CN¥12.11

Third quarter earnings released

New 90-day low: CN¥13.12

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥14.14

Shanghai Yongwei Biotechnology Co., Ltd. completed the acquisition of Guangdong Zhongqiang Pharmaceutical Co., Ltd. from Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317).

Earnings released

Guangdong Zhongsheng Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad